Cyramza® New Indication

The FDA has announced that Cyramza^® (ramucirumab) is now approved in combination with erlotinib as a first-line treatment for non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.¹

Prescribers can immediately place prescription orders with Onco360 for CYRAMZA as well as other cancer and supportive care medications

For more information on Cyramza, please visit cyramza.com.

¹https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-ramucirumab-plus-erlotinib-first-line-metastatic-nsclc.